
Restoril® is the brand name for temazepam, a prescription benzodiazepine primarily used for the short-term treatment of insomnia. It helps patients:
Fall asleep more quickly
Maintain sleep throughout the night (depending on individual response)
Improve overall sleep quality when non-drug methods, like sleep hygiene or behavioral therapy, are insufficient
Temazepam is generally prescribed for short-term use, typically a few weeks, because prolonged use may increase the risk of dependence or tolerance.
Temazepam is classified as a Schedule IV controlled substance in the United States. This classification reflects its potential for:
Sedation and cognitive impairment (drowsiness, impaired coordination, memory lapses)
Dependence and withdrawal risk if used long-term
Interactions with other central nervous system depressants, such as alcohol, opioids, or other sedatives
Regulatory safeguards include:
Prescriptions issued only by licensed healthcare providers
Limited refills and strict dosage oversight
Dispensing only through licensed pharmacies
Monitoring via prescription records and, in some states, Prescription Drug Monitoring Programs (PDMPs)
These rules help ensure safe use and minimize the risk of misuse or diversion.
Access to Restoril requires a valid prescription from a licensed healthcare provider. Legal avenues include:
In-Person Care
Physicians evaluate insomnia, overall health, and current medications
Prescriptions are tailored to the patient’s condition and monitored regularly
Telemedicine (where legally permitted)
Licensed telemedicine providers can prescribe Restoril following a full consultation
Prescriptions are sent to a licensed pharmacy for dispensing
Important: Restoril cannot be legally obtained online without a prescription from a licensed clinician.
Drowsiness, fatigue, or grogginess
Dizziness or unsteadiness
Memory impairment or difficulty concentrating
Respiratory depression, especially when combined with alcohol, opioids, or other sedatives
Complex sleep behaviors, such as sleepwalking, sleep-driving, or eating while asleep
Falls or accidents, particularly in older adults
Alcohol and other sedatives can amplify sedation and respiratory risks
Certain medications, including other CNS depressants or inhibitors of liver metabolism, may increase temazepam levels
Long-term or frequent use can lead to physical dependence and withdrawal symptoms if stopped abruptly
Tolerance may develop, reducing effectiveness over time
Clinicians monitor dosing and duration to minimize risk
Follow-up visits to assess effectiveness and side effects
Review of medications to prevent interactions
Guidance on tapering doses safely when discontinuing treatment
Patients prescribed Restoril should:
Take the medication exactly as prescribed
Avoid alcohol or other sedatives while using the drug
Store medication securely, away from children or others
Dispose of unused medication through authorized take-back programs
Report side effects, unusual sedation, or abnormal sleep behaviors promptly
Restoril® (temazepam) is a short-term prescription benzodiazepine for insomnia. Its Schedule IV classification reflects both its therapeutic benefit and the potential risks of sedation, dependence, and drug interactions. Legal access requires evaluation by a licensed clinician and dispensing through a licensed pharmacy, and safe use depends on strict adherence to prescribed dosing, monitoring, and patient education.
| Supporters | |||
| Name | Date | Amount | Comments |
| Total | $0.00 | ||